Inactive Instrument

China YCT International Group Inc. Stock Other OTC

Equities

US16945C1071

Pharmaceuticals

Dynamic Chart
Spring Pharmaceutical Group, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended December 31, 2018 CI
Spring Pharmaceutical Group, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2018 CI
China YCT International Group, Inc. has Changed its Name to Spring Pharmaceutical Group, Inc CI
China YCT International Group, Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended June 30, 2018 CI
China YCT International Group, Inc Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended September 30, 2017 CI
China YCT International Group, Inc Announces Financial Results for the Year Ending March 31, 2017 CI
China YCT International Group, Inc Appoints Li Dong to the Board of Directors CI
Shandong Yongchuntang Group Co., Ltd acquired 3% stake in Shandong Spring Pharmaceutical Co., Ltd. from China YCT International Group, Inc. CI
China YCT International Group Inc. Reports Earnings Results for the Fiscal Year Ended March 31, 2015 CI
CYIG Signs Strategic Cooperation Agreement with Xi'an Putian Pharmacy CI
China YCT International Group, Inc Reports Earnings Results for the Year Ended March 31, 2014 CI
L.Y.(HK) Biotech Limited cancelled the acquisition of China YCT International Group, Inc in a reverse merger transaction. CI
More news
Managers TitleAgeSince
Chief Executive Officer 69 88-12-31
Director of Finance/CFO 59 04-12-31
Chief Administrative Officer 52 -
Members of the board TitleAgeSince
Chief Executive Officer 69 88-12-31
Director/Board Member 68 03-12-31
Director/Board Member 73 09-04-05
More insiders
SPRING PHARMACEUTICAL GROUP, INC., formerly China YCT International Group, Inc., operates through two of its subsidiaries, Landway Nano Bio-Tech Group, Inc. (Landway Nano) and Shandong Spring Pharmaceutical Co., Ltd. (Shandong Spring Pharmaceutical). Through its subsidiaries, the Company is engaged in the distribution of health care supplement products, and in the development, manufacture and sales of Huoliyuan capsules, and in the development of the acer truncatum bunge planting bases and selling acer truncatum seed oil.
More about the company